Phase 3 Clinical Trial Results for TNX-103 and Aficamten Presented at ESC Congress 2026

Late-breaking clinical science sessions at the European Society of Cardiology (ESC) Congress 2026 are featuring the presentation of results from two significant Phase 3 trials today. These include the LEVEL trial for TNX-103 (oral levosimendan) in pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), and the ACACIA-HCM trial on aficamten's effect on cardiac structure and function in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.